
Drug de-escalation in lung cancer: are we nearly there yet?
While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability
While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability
According to Heine H. Hansen Award winner, Prof. Keith Kerr, pathologists can help translate scientific understanding into clinical practice
In the TROPION-Lung04 study, no new safety signals were observed with datopotamab deruxtecan plus durvalumab in patients with untreated advanced disease
In the KEYNOTE-671, improvements in event-free survival and overall survival were observed after four years of follow up
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial
The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer
Studies reveal promising evidence for the more precise tailoring of immunotherapy and the role of AI in improving response evaluation
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.